Evidence map›Paper›PMID 40098479›Full record

ArticleHuman vaccines & immunotherapeutics2025

Strategically striving to be more inclusive: A recommendation for gender-neutral human-papillomavirus vaccine policies.

Mary Jue Xu, Samuel Okerosi, Aslam Nkya, Katherine Van Loon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mary Jue XuDepartment of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4996-6362
Samuel OkerosiEar Nose and Throat Department, Kenyatta National Hospital, Nairobi, Kenya.
Aslam NkyaDepartment of Otorhinolaryngology, Muhimbili National Hospital, Dar es Salaam, Tanzania.
Katherine Van LoonDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization (WHO) has shifted from a multiple-dose human papillomavirus (HPV) vaccine schedule to a one-dose schedule prioritizing females aged 9-14 y. Given the burden of HPV-associated disease aside from cervical cancer and affecting both sexes, a shift toward emphasizing gender-neutral HPV vaccination strategies may improve vaccination coverage and more comprehensively address HPV-driven disease across both sexes, particularly for low- and middle-income countries.

Indexed as

Health PolicyPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsVaccinationAdolescentChildFemaleHumansImmunization ScheduleMaleVaccination CoverageWorld Health OrganizationPapillomavirus Vaccinesgender neutralHuman papillomavirusvaccination policy

Identifiers

PMID40098479
PMCPMC12934128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.